FDA Alignment Clears Path for Phase 3 Trial of Efzofitimod in Pulmonary Sarcoidosis
ATYR is trading near its 52-week low of $0.35 (10% above the low).
Summary
aTyr Pharma has reached alignment with the FDA on the design of a Phase 3 study for efzofitimod in pulmonary sarcoidosis, with study-related activities set to begin in Q4 2026. The Phase 3 study will enroll up to 372 patients, dose 5.0 mg/kg efzofitimod every 3 weeks for 54 weeks, with primary endpoint change in FVC at week 48 and key secondary endpoint KSQ-Lung score at week 48. This is a major regulatory milestone for the company's lead asset, which was recently prioritized after a 60% workforce reduction and the termination of the Kyorin collaboration. The FDA agreement removes a key uncertainty around the pivotal trial design, potentially accelerating the path to a registrational study. The company is also seeking shareholder approval for a reverse stock split to maintain Nasdaq listing, underscoring the importance of this clinical progress. Investors will watch for the actual trial initiation and any further details on endpoints and enrollment timelines.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The Phase 3 study will enroll up to 372 patients, dose 5.0 mg/kg efzofitimod every 3 weeks for 54 weeks, with primary endpoint change in FVC at week 48 and key secondary endpoint KSQ-Lung score at week 48.
At the time of this announcement, ATYR was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.8M. The 52-week trading range was $0.35 to $1.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.